Shanghai MicroPort EP MedTech Future Growth
Future criteria checks 5/6
Shanghai MicroPort EP MedTech is forecast to grow earnings and revenue by 59.4% and 29.9% per annum respectively. EPS is expected to grow by 59.4% per annum. Return on equity is forecast to be 4.7% in 3 years.
Key information
59.4%
Earnings growth rate
59.4%
EPS growth rate
Medical Equipment earnings growth | 23.9% |
Revenue growth rate | 29.9% |
Future return on equity | 4.7% |
Analyst coverage | Low |
Last updated | 27 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 922 | 133 | 64 | 111 | 3 |
12/31/2025 | 660 | 70 | 19 | 61 | 5 |
12/31/2024 | 469 | 33 | -33 | 21 | 5 |
3/31/2024 | 366 | 19 | -60 | -18 | N/A |
12/31/2023 | 329 | 6 | -80 | -38 | N/A |
9/30/2023 | 304 | 12 | -75 | -32 | N/A |
6/30/2023 | 281 | 4 | -82 | -39 | N/A |
3/31/2023 | 257 | -6 | -55 | -22 | N/A |
12/31/2022 | 260 | 3 | -41 | -9 | N/A |
9/30/2022 | 245 | -4 | -41 | -13 | N/A |
6/30/2022 | 221 | -7 | -26 | 2 | N/A |
3/31/2022 | 200 | -10 | -17 | 14 | N/A |
12/31/2021 | 190 | -12 | -16 | 21 | N/A |
12/31/2020 | 141 | 6 | -22 | 9 | N/A |
12/31/2019 | 117 | -15 | -10 | 0 | N/A |
12/31/2018 | 84 | -2 | 1 | 3 | N/A |
6/30/2018 | 77 | -5 | -2 | 7 | N/A |
3/31/2018 | 70 | -10 | -12 | -4 | N/A |
12/31/2017 | 62 | -14 | N/A | -14 | N/A |
9/30/2017 | 57 | -17 | N/A | -12 | N/A |
6/30/2017 | 53 | -19 | N/A | -9 | N/A |
3/31/2017 | 49 | -19 | N/A | -6 | N/A |
12/31/2016 | 46 | -19 | N/A | -3 | N/A |
12/31/2015 | 37 | -17 | N/A | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688351's forecast earnings growth (59.4% per year) is above the savings rate (2.9%).
Earnings vs Market: 688351's earnings (59.4% per year) are forecast to grow faster than the CN market (24.3% per year).
High Growth Earnings: 688351's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688351's revenue (29.9% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 688351's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688351's Return on Equity is forecast to be low in 3 years time (4.7%).